Multiple myeloma : therapeutic delivery of antibodies and aptamers

Pujol-Navarro, Neret and Al Qaraghuli, Mohammed M and Kubiak-Ossowska, Karina and Alsaadi, Manal M and Horne, Gillian A and Soutar, Richard L and Paspali, Elpiniki and Ferro, Valerie A and Williams, Mark TS and Mulheran, Paul A (2021) Multiple myeloma : therapeutic delivery of antibodies and aptamers. Therapeutic Delivery, 12 (10). pp. 705-722. ISSN 2041-5990

[thumbnail of Pujol-Navarro-etal-TD-2021-Multiple-myeloma-therapeutic-delivery-of-antibodies-and-aptamers] Text (Pujol-Navarro-etal-TD-2021-Multiple-myeloma-therapeutic-delivery-of-antibodies-and-aptamers)
Pujol_Navarro_etal_TD_2021_Multiple_myeloma_therapeutic_delivery_of_antibodies_and_aptamers.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 23 September 2022.

Download (670kB) | Request a copy from the Strathclyde author

    Abstract

    Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.

    ORCID iDs

    Pujol-Navarro, Neret, Al Qaraghuli, Mohammed M ORCID logoORCID: https://orcid.org/0000-0003-1823-6671, Kubiak-Ossowska, Karina, Alsaadi, Manal M, Horne, Gillian A, Soutar, Richard L, Paspali, Elpiniki, Ferro, Valerie A ORCID logoORCID: https://orcid.org/0000-0003-1967-3603, Williams, Mark TS and Mulheran, Paul A ORCID logoORCID: https://orcid.org/0000-0002-9469-8010;